Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07526545 · ClinicalTrials.gov registry record · NA

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

A NA study, sponsored by University of Michigan Rogel Cancer Center.

Not yet
Registry status
NA
Development phase
800
Enrollment target

NCT07526545: Clinical Trial NA study, sponsored by University of Michigan Rogel Cancer Center.

NCT07526545 is a NA study that has not yet begun recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 800 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07526545, a NA study, has not yet begun recruiting, sponsored by University of Michigan Rogel Cancer Center.

NOT YET RECRUITING
Registry status
NA
Development phase
800 participants
Enrollment target

Study Summary

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Primary Outcome

Will compare the proportions of patients with detected csPCa in the intervention and control arms (p1 and p2, respectively) using the OBrien Fleming stopping boundaries which control the overall one-sided Type I error rate to be less than .10.

Interventions

  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Biopsy Procedure
  • OTHER Electronic Health Record Review
  • DEVICE Diagnostic Procedure

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2026-09-01
Est. Completion 2030-03-01
Phase NA

What is known before NCT07526545 opens enrollment

NCT07526545 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).

The record links to 0 conditions, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT07526545 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07526545 about?

NCT07526545 is a clinical study titled "Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial". This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggress...

What is the current status of trial NCT07526545?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2026-09-01. Estimated completion is 2030-03-01.

What interventions are being tested in trial NCT07526545?

The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Biopsy Procedure (PROCEDURE), Electronic Health Record Review (OTHER), Diagnostic Procedure (DEVICE).

Who is sponsoring clinical trial NCT07526545?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07526545's enrollment target sits among peer trials

800 135th of 2000 higher than 1,861 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07526545, the US trial registry maintained by the National Library of Medicine. NCT07526545 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.